跳转至内容
Merck

Y0000853

氟伏沙明

European Pharmacopoeia (EP) Reference Standard

别名:

伏氟沙明马来酸盐, (E)-5-甲氧基-1-(4-三氟甲苯基)-1-戊酮-O-(2-胺乙肟基)-马来酸盐

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C15H21F3N2O2 · C4H4O4
CAS号:
分子量:
434.41
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

fluvoxamine

製造商/商標名

EDQM

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

2-8°C

SMILES 字串

COCCCC/C(C1=CC=C(C(F)(F)F)C=C1)=N\OCCN.OC(/C=C\C(O)=O)=O

InChI

1S/C15H21F3N2O2.C4H4O4/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18;5-3(6)1-2-4(7)8/h5-8H,2-4,9-11,19H2,1H3;1-2H,(H,5,6)(H,7,8)/b20-14+;2-1-

InChI 密鑰

LFMYNZPAVPMEGP-PIDGMYBPSA-N

基因資訊

human ... SLC6A4(6532)

正在寻找类似产品? 访问 产品对比指南

一般說明

本品按现行药典规定交付。所有为支持本产品而提供的信息,包括SDS和任何产品信息单均由药典颁发机构制定并发布。 如需进一步信息和支持,请访问现行药典网站。

應用

用于系统适用性的氟伏沙明EP参考标准品的预期用途是欧洲药典规定的实验室测试。

包裝

本品按照现行药典要求提供。有关当前单位数量,请见EDQM 参考目录

其他說明

可能适用相应的销售限制。

象形圖

Exclamation mark

訊號詞

Warning

危險聲明

防範說明

危險分類

Acute Tox. 4 Oral

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Shohei Matsunami et al.
Behavioural brain research, 233(2), 577-586 (2012-06-12)
Behavioural effects of fluvoxamine (FLV, selective serotonin reuptake inhibitor) were examined in 1-2 week old domestic chicks. Chicks were tested in an I-shaped maze equipped with a feeder (ON feeder) that served 1 or 2 grains of millet at gradually
Md Shenuarin Bhuiyan et al.
Journal of pharmacological sciences, 121(3), 177-184 (2013-02-23)
Depression is associated with a substantial increase in the risk of developing heart failure and is independently associated with increased cardiovascular morbidity and mortality. Inversely, cardiovascular disease can lead to severe depression. Thus, therapy with selective serotonin reuptake inhibitors (SSRIs)
Donatella Marazziti et al.
Human psychopharmacology, 27(4), 397-402 (2012-07-19)
In this study, we explored the possible relationships between plasma fluvoxamine levels and clinical features and/or response in adult obsessive-compulsive disorder (OCD) patients treated with this drug for 6 months. Twenty OCD outpatients of both sexes who were already taking
Anton J L M van Balkom et al.
Psychotherapy and psychosomatics, 81(6), 366-374 (2012-09-12)
To compare the effectiveness of second-step treatment with cognitive therapy (CT) versus fluvoxamine in patients with obsessive-compulsive disorder (OCD) who are nonresponsive to exposure in vivo with response prevention (ERP). A 12-week randomized controlled trial at an outpatient clinic in
Eiko Sunami et al.
Internal medicine (Tokyo, Japan), 51(10), 1187-1193 (2012-06-13)
Antidepressants have been recommended for the treatment of post-stroke depression (PSD). The purpose of this study was to evaluate the effect of fluvoxamine maleate, a selective serotonin re-uptake inhibitor (SSRI), on depressive state, sleep disturbance, and serum melatonin levels in

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门